Mast Therapeutics, Inc. (NASDAQ:SVRA) Director Yuri Pikover Purchases 50,000 Shares

Mast Therapeutics, Inc. (NASDAQ:SVRA) Director Yuri Pikover purchased 50,000 shares of the company’s stock in a transaction on Friday, October 27th. The stock was purchased at an average cost of $7.85 per share, for a total transaction of $392,500.00. Following the purchase, the director now directly owns 150,000 shares in the company, valued at $1,177,500. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Mast Therapeutics, Inc. (NASDAQ SVRA) traded up $0.48 during trading hours on Friday, hitting $9.53. The company had a trading volume of 125,400 shares, compared to its average volume of 155,450. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.83 and a current ratio of 9.15. Mast Therapeutics, Inc. has a twelve month low of $4.60 and a twelve month high of $16.10.

TRADEMARK VIOLATION NOTICE: “Mast Therapeutics, Inc. (NASDAQ:SVRA) Director Yuri Pikover Purchases 50,000 Shares” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2017/11/13/mast-therapeutics-inc-svra-director-yuri-pikover-buys-50000-shares-of-stock.html.

Several analysts have issued reports on the company. Roth Capital dropped their price target on Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, October 31st. Canaccord Genuity lifted their target price on Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 30th. Jefferies Group LLC assumed coverage on Mast Therapeutics in a research report on Friday, September 22nd. They issued a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research raised Mast Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 target price on the stock in a research report on Tuesday, September 19th. Finally, JMP Securities assumed coverage on Mast Therapeutics in a research report on Monday, September 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Mast Therapeutics has a consensus rating of “Buy” and a consensus target price of $21.30.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply